Medically reviewed by Jeffrey S. Lander, MD ATTR-CM is an acronym for the medical condition called transthyretin amyloid cardiomyopathy. There are two causes of ATTR-CM, an inherited gene mutation and ...

Objectives Cardiac amyloidosis (CA) is a rare and underdiagnosed disease associated with a high mortality rate. Although, in the last decade, there has been increasing attention in the literature to ...

Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...

Using brain gene expression maps from the Allen Human Brain Atlas, the researchers tested the degree to which Alzheimer’s risk genes explain the patterns of both actual and residual tau. This allowed ...

Researchers at the Federal University of São Carlos (UFSCar) in the state of São Paulo, Brazil, are developing a panel of ...

Of the 258 participants, 195 were cognitively asymptomatic, 34 had mild cognitive impairment, 23 had dementia, and six had an ...

Scientists are just beginning to understand the microbes that have been with us for millennia — the so-called microbiome, ...

It’s not always obvious which of the multitude of species of bacteria riding around in us should be classified as germs and ...

A study published in Cell Stem Cell reveals that some mutations in blood stem cells might help protect against late-onset ...

Hereditary transthyretin amyloidosis (hATTR) with polyneuropathy is a rare disorder passed down in families that gets worse over time. It’s a result of a change in a gene, also called a mutation.

Voyager Therapeutics presents data on tau silencing therapy VY1706 and anti-amyloid therapy at ASGCT 2025.

CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...